The 28th Annual Meeting of the Japanese Society
for Biomedical Mass Spectrometry
| Program | September
25 (Thu.) |
Japanesee |
@
| September
26 (Fri.) |
| 9:00 | Oral Presentation X
(G18|G21) |
| G18 | Identifications of modified octapeptides containing cysteine of transthyretin |
| by iontrap tandem mass spectrometry | |
| Toyofumi NAKANISHI1ETakako SATO1E2EAkira SHIMIZU1 | |
| 1Department of Clinical Pathology, Osaka Medical College | |
| 2Department of Neurology, Osaka University Graduate School of Medicine | |
| G19 | Quantitative measurement of hemoglobin A1c by stable isotope dilution |
| method | |
| Ken IGUCHI1EToyofumi NAKANIAHI2EAkira SHIMIZU1E2 | |
| 1Central Clinical Laboratory, Osaka Medical College Hospital | |
| 2Department of Clinical Pathology, Osaka Medical College | |
| G20 | Detection of S-homocysteinyl transthyretin in plasma and serum from |
| patients
with hyperhomocysteinemia by LC-ESIMS |
|
| Takako SATO1EToyofumi NAKANISHI2EJorn Oliver SASS3ESaburo SAKODA1 | |
| Akira SHIMIZU2 | |
| 1Department of Neurology, Osaka University Graduate School of Medicine | |
| 2Department of Clinical Pathology, Osaka Medical College | |
| 3University of Freiburg Childrenfs Hospital, Laboratory of Metabolism, | |
| Germany | |
| G21 | Analysis of medium chain acyl-CoA synthetase by LC-ESI-MS/MS |
|
Fumiyo KASUYA1ETakao TATSUKI1EKyoko SASAKI2EYoji KITAMURA1EKazuo |
|
| IGARASHI1 | |
| 1Faculty of Pharmaceutical Sciences, Kobegakuin University | |
| 2Jasco International Co., Ltd. |
| 10:00 | Oral Presentation Y
(G22|G25) |
| G22 | Mass
spectrometric analysis of single nucleotide polymorphisms (SNPs) |
| Kentaro TAKI1EIsao AOYAMA1EAtsushi ENOMOTO1EFumio TAKAYAMA1E | |
| Naohito TAKEDA2EToshimitsu NIWA1 | |
| 1Department of Clinical Preventive Medicine, Nagoya University Hospital | |
| 2Faculty of Pharmacy, Meijo University | |
| G23 | Evaluation of sphingolipids in vitreous body from a
patient with Gaucher |
| disease by DE MALDI-TOF/MS | |
| Takehisa FUJIWAKI1ESeiji YAMAGUCHI1EMasaru TASAKA1EMasaki | |
| TAKAYANAGI2ETamotsu TAKETOMI3 | |
| 1Department of Pediatrics, Shimane Medical University | |
| 2Department of Pediatrics, Chiba Childrenfs Hospital | |
| 3Department of Biochemistry, Research Center on Aging and Adaptation, | |
| Shinshu University School of Medicine | |
| G24 | Semiquantification of ceramide trihexoside in aortic valve from patient with |
| Fabry disease analyzed by MALDI-TOFMS | |
| Masaru TASAKA1ETakehisa FUJIWAKI1ENobuyuki TAKAHASHI2EYou | |
| MURAKAMI2EToshio SHIMADA2ESeiji YAMAGUCHI1 | |
| 1Department of Pediatrics, Shimane Medical University | |
| 2Cardiovascular Division of Internal Medicine, Shimane Medical University | |
| G25 | Structure analysis of protein anchored on ibuprofen by MALDI-TOFMS and |
| chiral characterication by immunoblotting | |
| Shigeo IKEGAWA | |
| Department of Bioanalytical Pharmaceutics, Faculty of Pharmaceutical | |
| Sciences, Kinki University |
| 11:00 | Coffee Break |
@
| 11:10 | Special Lecture |
| Drug facilitated sexual assault (DFSA) and toxicological analysis: testing for | |
| the undetectable by mass spectrometry | |
| Pascal KINTZ and Marion VILLAIN | |
| Institut de Médecine Légale, 11 rue Humann, F-67000 Strasbourg, France |
@
| 12:00 |
Lunch Time |
@
| 13:30 | WorkshopU |
| W2-1 | Characteristics of gChemo View Softwareh that automates neonatal screening |
| using tandem mass spectrometry | |
| Hidekazu MIYAKODA, Yuriko OZEKI, Tetsuo KOKAJI, Yasuhiko MAEKAWA | |
| Applied Biosystems Japan Ltd. | |
| W2-2 | An LC and LC/MS (n) system for proteomic analysis |
| Hiroyuki MURAKITA, Junko IIDA | |
| Analytical & Measuring Instruments Division, Shimadzu Corporation | |
| W2-3 | State-of-the-art technologies for proteomics |
| Masahiko TAKINO | |
| Yokogawa Analytical Systems Inc., Application Center | |
| W2-4 | Development and applications of CE-MS interface for LC-TOFMS |
| Yutaka TAKAHASHI ETetsuichiro MORITAEKenji NAGATOMOEJunichi | |
| OSUGAEKiyotaka KONUMAEJun
TAMURA |
|
| JEOL Ltd. | |
| W2-5 | Biomarker discovery using SELDI-TOF-MS |
| Kenji SAITOH | |
| Ciphergen Biosystems K.K. Yokohama Laboratory |
| 15:10 | Closing Remark |
@
@@